Tag

Novo Nordisk

Promoting Quality Excellence and Cultivating a Culture of Proactive Operations
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Promoting Quality Excellence and Cultivating a Culture of Proactive Operations

Søren Thuesen Pedersen is Senior Director, External Affairs, Regulatory Policy and Intelligence at Novo Nordisk. He is a Chemical Engineer by education and has been working 30 years in Novo Nordisk. During that that time he has been engaged and lead different areas within Manufacturing, QC-Laboratory and CMC Manufacturing Development. He has been one of the founding fathers of the Novo Nordisk External Requirements’ Process; How does Novo Nordisk ensure compliance of new external requirements? Mr. Pedersen is currently responsible for the External Representation and Advocacy strategy out of Novo Nordisk’s GMP&Q area and represents Novo Nordisk in various associations ISPE, EFPIA, IFPMA and BIO. Specifically, Mr. Pedersen is a member of the EFPIA Manufacturing Quality Expert Group (MQEG) since 2019 and member of the Board of Directors in IQ Consortium.

He has furthermore been member of the Novo Nordisk Board of Directors for 12 years as an elected employee representative.

His spare time interests include Danish and EU Politics.

Martin P. Müller joined Novo Nordisk in 2014 and currently directs development projects for innovative technologies within Aseptic Manufacturing, with particular focus on formulation, filling, wash & sterilization, and environmental monitoring.

Before moving to production in Novo Nordisk, Mr. Müller has served 10 years in Device R&D, driving the digital agenda of the area, external affairs and QMS-processes and project management, among others.

Mr. Müller earned his Master of Arts from Humboldt University Berlin, Germany, and his Master of Business Administration from Copenhagen Business School, Denmark.

Continue reading
Martin Müller & Søren Thuesen Pedersen of Novo Nordisk — Collaboration Among Industry Peers to Move the Life Sciences Forward
LIFE SCIENCES, VIDEO, LIFE SCIENCES, PODCAST

Martin Müller & Søren Thuesen Pedersen of Novo Nordisk — Collaboration Among Industry Peers to Move the Life Sciences Forward

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Martin Müller and Søren Thuesen Pedersen of Novo Nordisk to talk about opportunities biopharmaceutical manufacturers have to work together to lower costs, standardize equipment, build win-win scenarios for procurement and supply chain, and similar initiatives where competitive advantage and IP are not at stake, but costs and compliance and other performance metrics can be improved through joining forces and agreeing on things collectively rather than each company having to reinvent its own wheel on every issue. Building upon their earlier presentation that covered much of the same content, we discuss what would that collaboration look like in real terms? What does getting started look like, and how can interested companies join the ongoing conversations and deliberations? For all that and more, give this episode a listen!

Continue reading
Panel: Optimizing Technical Operations: Best Practices for Manufacturing Next-Gen Medicines
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel: Optimizing Technical Operations: Best Practices for Manufacturing Next-Gen Medicines

Anshul Mangal is President of Project FARMA and Precision ADVANCE. Anshul founded and grew PF into a leading global biologics and advanced therapy engineering consulting firm. Under Anshul’s leadership, PF has partnered with over 100+ therapeutic innovators, developed state-of-art manufacturing facilities for complex biologics and pioneered the industrialization of advanced therapies including many commercially approved cell and gene therapies. PF was acquired by Precision Medicine Group in 2020 to be the cornerstone of Precision ADVANCE. ADVANCE is a collection of Precision’s services uniquely focused on the complexities of research and clinical development, regulatory, manufacturing, and commercial needs to successfully bring an advanced therapy to market.  In addition, Anshul is an investor, board member and advisor at several biotech organizations.  Prior to PF, Anshul was a patent litigator at Jones Day and a consultant at Morgan Stanley & Discover Financial Services.

Continue reading